Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Gilead Sciences

Status and phase: Terminated; Phase 4

Conditions: Polyneuropathy; Coronary Artery Disease; Peripheral Nervous System Diseases; Pain

Treatments: Drug: Placebo; Drug: Ranolazine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00832572

CVT 3042

Details and patient eligibility

About

This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.

Eligibility required neurological examination by the study doctor and assessment of the patient's pain. Eligible participants were randomized to receive blinded study medication for a total of 12 weeks.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females aged ≥ 18 years
• Coronary artery disease with a clinically diagnosed peripheral neuropathy
• Willing and able to provide signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
• Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff

Exclusion criteria

• History of allergy or intolerance to ranolazine
• Any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see Appendix E)
• In the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug
• In the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)
• Use of any experimental or investigational drug or device within 30 days prior to screening
• Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in Inclusion Criterion 4)
• Had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization
• Clinically significant hepatic impairment
• Had end-stage renal disease requiring dialysis
• Psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation
• Positive pregnancy test at Baseline (pre-randomization, Day 0)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

5 participants in 2 patient groups

Placebo-Ranolazine

Experimental group

Description:

Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.

Treatment:

Drug: Placebo

Drug: Ranolazine

Ranolazine-Placebo

Experimental group

Description:

Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.

Treatment:

Drug: Placebo

Drug: Ranolazine